Volume 8.12 | Mar 31

Cord Blood News 8.12 March 31, 2016
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Rapamycin-Induced Hypoxia Inducible Factor 2A Is Essential for Chondrogenic Differentiation of Amniotic Fluid Stem Cells
Researchers investigated the effects of mammalian target of rapamycin complex 1 modulation on the expression of SOX9 and on its downstream targets during chondrogenic differentiation of amniotic fluid stem cells. [Stem Cells Transl Med] Abstract
Learn more about new StemSpan™ Erythroid Expansion Medium. Combine with Erythroid Expansion Supplement to generate 1000s of erythroid cells per input human CD34+ cell in ACF conditions.
PUBLICATIONS (Ranked by impact factor of the journal)
A Human Amnion-Derived Extracellular Matrix-Coated Cell-Free Scaffold for Cartilage Repair: In Vitro and In Vivo Studies
Scientists developed a novel human amniotic mesenchymal cells-derived extracellular matrix-coated polylactic-co-glycolic acid scaffold, examined its property on mesenchymal cells, and investigated its potential as a cell-free scaffold for cartilage repair. [Tissue Eng Part A] Abstract

DNA Methylation of Cord Blood Cell Types: Applications for Mixed Cell Birth Studies
Using magnetic bead sorting, the authors isolated cord blood cell types (nucleated red blood cells, granulocytes, monocytes, natural killer cells, B cells, CD4+ T cells, and CD8+ T cells) from 17 live births at Johns Hopkins Hospital. They compared cell type specific signatures in cord to each other and methylation at 49.2% of CpG sites on the array differed by cell type. [Epigenetics] Abstract

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using Tailored Busulphan-Based Conditioning Regimen: Single Center Experience
A total of 38 pediatric patients, median age was eight years, suffering from hemoglobinopathy were treated. Sources of stem cells were peripheral blood in 30 transplants, bone marrow in seven transplants, and cord blood in three transplants. Overall survival above 90% in patients undergoing their first transplant was demonstrated using busulphan-based conditioning regimens. [Biol Blood Marrow Transplant] Abstract

Enhanced Cell Survival and Paracrine Effects of Mesenchymal Stem Cells Overexpressing Hepatocyte Growth Factor Promote Cardioprotection in Myocardial Infarction
Scientists aimed to evaluate the cardioprotective effects of mesenchymal stem cells (MSCs) overexpressing hepatocyte growth factor (HGF) in a mouse model of myocardial infarction. The apoptosis of umbilical cord-derived MSCs (UC-MSCs) and HGF-UC-MSCs under normoxic and hypoxic conditions was detected. [Exp Cell Res] Abstract

Alginate/PEG Based Microcarriers with Cleavable Crosslinkage for Expansion and Non-Invasive Harvest of Human Umbilical Cord Blood Mesenchymal Stem Cells
A series of alginate/PEG (AL/PEG) semi-interpenetrating network microcarriers were prepared. AL/PEG microcarriers can support the attachment and proliferation of human umbilical cord blood mesenchymal stem cells. [Mater Sci Eng C Mater Biol Appl] Abstract

Anti-Inflammatory Effect of Mesenchymal Stromal Cell Transplantation and Quercetin Treatment in a Rat Model of Experimental Cerebral Ischemia
Scientists investigated the synergistic effect of quercetin administration and transplantation of human umbilical cord mesenchymal stromal cells following middle cerebral artery occlusion in rat. [Cell Mol Neurobiol] Abstract

Get More of the Cells You Need with StemSpan™ CD34+ Cell Expansion Supplement and StemSpan™ SFEM
Key Transcription Factors in the Differentiation of Mesenchymal Stem Cells
The authors critically discuss and evaluate the role of transcription factors and related signaling pathways that affect the differentiation of mesenchymal stem cells toward adipocytes, chondrocytes, osteocytes, skeletal muscle cells, cardiomyocytes, and smooth muscle cells. [Differentiation] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Cesca Therapeutics’ Indian Subsidiary Expands Cord Blood Banking Services to Additional Hospitals in the Fortis Healthcare Network
Cesca Therapeutics Inc. announced that its wholly-owned subsidiary in India, TotiPotentRX, has expanded its private cord blood banking services into several hospitals within the Fortis Healthcare network in South and West India. [Cesca Therapeutics Inc.] Press Release

Children’s Hospital Los Angeles to Initiate Clinical Trial for Kids with Treatment-Resistant Leukemia
The Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia. [Children’s Hospital Los Angeles] Press Release

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (Melphalan) for Injection
Ligand Pharmaceuticals Incorporated announced that Spectrum Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA™ for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with MM, and 2) for the palliative treatment of patients with MM for whom oral therapy is not appropriate. [Ligand Pharmaceuticals Incorporated] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Stem Cells & Regenerative Medicine Congress
May 18-20, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Scientist – Hematological Malignancies (Max Delbruck Center for Molecular Medicine in the Helmholtz Association)

Postdoctoral Research Associate – Pediatric Acute Lymphoblastic Leukemia (University of Pittsburgh)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Research Fellow – Erythropoiesis (New York Blood Center)

Postdoctoral Fellow – Stem Cell Biology and Regenerative Medicine (Cleveland Clinic)

Postdoctoral Positions – Immunology, Cancer, and Stem Cells (University of Connecticut)

PhD Position – Stem Cells and Transplantation (University of Geneva)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us